lapatinib has been researched along with Pulmonary Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Aqtash, T; Albashaireh, D; Alkhatib, Y; Awdish, R | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
2 other study(ies) available for lapatinib and Pulmonary Hypertension
| Article | Year |
|---|---|
The role of tyrosine kinase inhibitor "Lapatinib" in pulmonary hypertension.
Topics: Aged; Antineoplastic Agents; Cardiac Catheterization; Echocardiography; Humans; Hypertension, Pulmonary; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors | 2016 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |